Evidence map›Paper›PMID 35102706›Full record

ArticleCancer medicine2022

Signatures of malignant cells and novel therapeutic targets revealed by single-cell sequencing in lung adenocarcinoma.

Jiaqi Liang, Zhencong Chen, Yiwei Huang, Guoshu Bi, Yunyi Bian, Xing Jin, Huan Zhang, Qihai Sui, Cheng Zhan, Qun Wang

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. iScience · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jiaqi LiangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhencong ChenDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yiwei HuangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Guoshu BiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yunyi BianDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xing JinDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Huan ZhangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qihai SuiDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Cheng ZhanDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8745-9276
Qun WangDepartment of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-4853-1727
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSingle-cell transcriptomics has been used to investigate various tumors to elucidate the molecular distinction of all cell type compositions of a complex mix.

aimsThis study aimed to investigate malignant-cell-specific genes to explore diagnostic and therapeutic biomarkers using single-cell transcriptomic data of lung adenocarcinoma. MATERIALS &

methods10X single-cell RNA-seq data of fourteen patients with lung adenocarcinoma were analyzed. Genes that expressed differentially and those with higher confidence to distinguish tumor cells from normal cells were picked out using the ROC curves. The LASSO regression method was used to select most markedly correlated genes to predict the malignancy of every single cell within a model. We also conducted further experiments to determine their roles in lung cancer in vitro.

resultsTwenty two thousand four hundred and ninety one tumor and 181 666 normal single cells were analyzed where 369 genes were found to be specifically expressed in single malignant cells. Seventy of them, encoding secreted or membrane-bound proteins, showed involvement in cell-to-cell communications in tumor biology. KRT18 and the other six genes were identified as predictors to distinguish single malignant cells and were integrated to construct an accurate (96.1%) predicting model. Notably, IRX2, SPINK13, and CAPN8 outperformed the other four genes. Further experiments confirmed the upregulation of them in lung adenocarcinoma at both tissue and cell levels. Proliferative capacities of lung adenocarcinoma cells were attenuated by knocking-down of either of them. However, targeting CAPN8, IRX2, or SPINK13 hardly exerted a cytotoxic effect on these cells. DISCUSSION: Apart from the current model, similar tools were still warranted using single-cell RNA-seq data of more types of tumors. The three genes identified as potential therapeutic targets in the present study still need to be validated in more in lung cancer.

conclusionOur model can aid the analyses of single-cell sequencing data. CAPN8, IRX2, and SPINK13 may serve as novel targets of targeted and immune-based therapies in lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungLung NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansTranscriptomeBiomarkers, Tumorlung adenocarcinomasingle-cell transcriptomicstherapeutic targets

Identifiers

PMID35102706
PMCPMC9160812
OpenAlexW4210734786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.